FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380626354> ?p ?o ?g. }

• W4380626354 abstract "Abstract Background and Aims Iptacopan (LNP023) is a first-in-class, oral, proximal complement inhibitor that specifically binds to Factor B and inhibits the alternative complement pathway (AP). Current Phase III studies of iptacopan focus on diseases associated with AP activation, such as paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulonephritis (C3G), IgA nephropathy (IgAN), and atypical hemolytic uremic syndrome. The liver is the primary route of iptacopan elimination. Based on a previous healthy volunteer pharmacokinetic (PK) study, the contribution of the renal route of iptacopan elimination was measured to be low, approximately 14%. A population PK (PopPK) analysis was done to further quantify the effect of renal impairment on iptacopan PK. Method A PopPK dataset pool was created by pooling across 6 Phase II/III studies in PNH, C3G, and IgAN indications. The pool comprised patient data on the two highest dose levels (100 and 200 mg bid) and included 2439 datapoints in 234 unique patients. Factors (baseline characteristics) that could possibly affect exposure, body weight, age, gender, ethnicity, and eGFR (mL/min/1.73 m2) at baseline were investigated. The range of eGFR was 27.4 to 142.8 mL/min/1.73 m2. Age, ethnicity, and body weight were included as the significant covariates in the final model. Results The median eGFR was 87.5 mL/min/1.73 m2. As shown in the table below, the PopPK model detected a significant (p = 4.3 × 10−11) but modest effect of eGFR on simulated mean AUC0-24. At an eGFR of 34.3, AUC0-24 is expected to increase by only 38%, compared with median eGFR. Changes of eGFR of ≤15% with respect to median eGFR were observed with eGFR range between 59.7 and 132.0 mL/min /1.73 m2. Conclusion Consistent with previously observed primarily hepatic clearance of iptacopan in preclinical and clinical studies, renal impairment down to an eGFR of 34.3 did not have a clinically meaningful effect on iptacopan PK. Currently, iptacopan PK in patients with eGFR &lt;30 mL/min/1.73 m2 is being explored. These results support the use of iptacopan in patients with mild and moderate renal impairment." @default.
• W4380626354 created "2023-06-15" @default.
• W4380626354 creator A5013126665 @default.
• W4380626354 creator A5044897328 @default.
• W4380626354 creator A5066994722 @default.
• W4380626354 creator A5073497094 @default.
• W4380626354 creator A5080807595 @default.
• W4380626354 creator A5083000448 @default.
• W4380626354 date "2023-06-01" @default.
• W4380626354 modified "2023-09-27" @default.
• W4380626354 title "#4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS" @default.
• W4380626354 doi "https://doi.org/10.1093/ndt/gfad063c_4447" @default.
• W4380626354 hasPublicationYear "2023" @default.
• W4380626354 type Work @default.
• W4380626354 citedByCount "0" @default.
• W4380626354 crossrefType "journal-article" @default.
• W4380626354 hasAuthorship W4380626354A5013126665 @default.
• W4380626354 hasAuthorship W4380626354A5044897328 @default.
• W4380626354 hasAuthorship W4380626354A5066994722 @default.
• W4380626354 hasAuthorship W4380626354A5073497094 @default.
• W4380626354 hasAuthorship W4380626354A5080807595 @default.
• W4380626354 hasAuthorship W4380626354A5083000448 @default.
• W4380626354 hasBestOaLocation W43806263541 @default.
• W4380626354 hasConcept C112705442 @default.
• W4380626354 hasConcept C126322002 @default.
• W4380626354 hasConcept C159641895 @default.
• W4380626354 hasConcept C2777288759 @default.
• W4380626354 hasConcept C2777346216 @default.
• W4380626354 hasConcept C2779978075 @default.
• W4380626354 hasConcept C2908647359 @default.
• W4380626354 hasConcept C71924100 @default.
• W4380626354 hasConcept C90924648 @default.
• W4380626354 hasConcept C99454951 @default.
• W4380626354 hasConceptScore W4380626354C112705442 @default.
• W4380626354 hasConceptScore W4380626354C126322002 @default.
• W4380626354 hasConceptScore W4380626354C159641895 @default.
• W4380626354 hasConceptScore W4380626354C2777288759 @default.
• W4380626354 hasConceptScore W4380626354C2777346216 @default.
• W4380626354 hasConceptScore W4380626354C2779978075 @default.
• W4380626354 hasConceptScore W4380626354C2908647359 @default.
• W4380626354 hasConceptScore W4380626354C71924100 @default.
• W4380626354 hasConceptScore W4380626354C90924648 @default.
• W4380626354 hasConceptScore W4380626354C99454951 @default.
• W4380626354 hasIssue "Supplement_1" @default.
• W4380626354 hasLocation W43806263541 @default.
• W4380626354 hasOpenAccess W4380626354 @default.
• W4380626354 hasPrimaryLocation W43806263541 @default.
• W4380626354 hasRelatedWork W1964391114 @default.
• W4380626354 hasRelatedWork W1990335353 @default.
• W4380626354 hasRelatedWork W2028521696 @default.
• W4380626354 hasRelatedWork W2065005216 @default.
• W4380626354 hasRelatedWork W2089699421 @default.
• W4380626354 hasRelatedWork W2154372624 @default.
• W4380626354 hasRelatedWork W2377624422 @default.
• W4380626354 hasRelatedWork W2803203200 @default.
• W4380626354 hasRelatedWork W3134051803 @default.
• W4380626354 hasRelatedWork W3151787567 @default.
• W4380626354 hasVolume "38" @default.
• W4380626354 isParatext "false" @default.
• W4380626354 isRetracted "false" @default.
• W4380626354 workType "article" @default.